Shanghai Fosun Pharma halts share trading

Shanghai Fosun Pharmaceutical (Group) Co Ltd, a China-based drug maker listed on Hong Kong stock exchange, announced trading halt on Thursday pending an important announcement.

On May 9, 2016, Fosun Pharma said it made a non-binding proposal to acquire majority stake from the existing shareholders of Hyderabad-based Gland Pharma.

The trading halt assumes significance in the backdrop of Fosun's bid to acquire Gland Pharma, according to trade analysts.

"At the request of Shanghai Fosun Pharmaceutical (Group) Co Ltd (the company), trading in the shares (stock code: 02196) of the company on The Stock Exchange of Hong Kong Limited will be halted with effect from 9 am on Thursday, July 28, 2016, pending the release of an announcement containing inside information in relation to a possible notifiable transaction," Fosun Pharma said in a regulatory filing.

Gland Pharma official were not available for comments.

An e-mail sent to Fosun Pharma remained unanswered.

Gland Pharma, incorporated in 1978, is engaged in the manufacture of injectable drugs.

It is the first injectable drug manufacturer in India which has been approved by the United States Food and Drug Administration and has obtained the Good Manufacturing Practice Certification in various markets in the world.

Its main business model is joint development of products and introduction of licenses to provide all global major pharmaceutical companies with the manufacturing services in relation to injectable generic drugs.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel